Pharminent

NICE green lights Keytruda for second-line lung cancer

Merck & Co’s oncology treatment backed in draft guidance for NSCLC
http://www.pmlive.com/pharma_news/nice_green_lights_keytruda_for_second-line_lung_cancer_1179774

Filed under: Cancer, Immunotherapy